Logo Image
News
Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Media
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsShortsTraining Academy
Conferences
Conference CoverageConference Listing
Publications
More
CME/CE
Continuing Education
Resources
Case-Based Digest Rx Road MapEventsAdvanced Practice Corner
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Partners
  • Brain Cancer
  • Breast Cancer
    • Metastatic Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Gastric Cancers
  • Genitourinary Cancer
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Cervical Cancer
    • Ovarian Cancer
  • Head and Neck Cancers
  • Hematology
    • Leukemia
    • Graft-Vs-Host Disease
    • Myeloproliferative Neoplasms
    • Multiple Myeloma
    • Lymphoma
  • Lung Cancer
  • Pediatric Cancer
  • Sarcomas
  • Skin Cancer
    • Melanoma
Advertisement

Gary H. Lyman, MD, MPH

Advertisement

Articles by Gary H. Lyman, MD, MPH

Gary H. Lyman on the Immediate and Long-Term Effects of Febrile Neutropenia

ByGary H. Lyman, MD, MPH
June 8th 2016

Gary H. Lyman, MD, MPH, Fred Hutchinson Cancer Research Center, discusses the immediate and long-term effects of febrile neutropenia.

Advertisement

Latest Updated Articles

  • Gary H. Lyman on the Immediate and Long-Term Effects of Febrile Neutropenia
    Gary H. Lyman on the Immediate and Long-Term Effects of Febrile Neutropenia

    June 8th 2016



Advertisement
Advertisement

Trending on Oncology Nursing News

1

Managing Rash and Stomatitis With Daraxonrasib in Pancreatic Cancer

2

FDA Approves Oral Nilotinib Tablets for Ph+ CML

3

Nursing Guide to Managing Lorlatinib in ALK+ NSCLC: 7-Year CROWN Insights

4

GLP-1 RAs Linked to Lower HR+ Breast Cancer Risk and Improved Survival

5

Pembrolizumab Improves 7-Year OS in Early-Stage TNBC: KEYNOTE-522 Final Data

  • About Us
  • Editorial Board
  • Contact Us
  • CancerNetwork.com
  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Advertise
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us